Aptose Biosciences announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has executed a wide array of business transactions totaling more than $3.7B, with healthcare focus in clinical testing, oncology, neurological, and orphan diseases indications. “Fletcher’s financial and business oversight has proven to be instrumental as we continue to evolve our business and operations strategies,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “He brings the strategic leadership necessary at a time of significant opportunity for Aptose.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APTO:
- Aptose Biosciences price target lowered to $18 from $23 at RBC Capital
- Aptose Biosciences reports Q3 EPS ($1.76), consensus ($2.05)
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- APTO Earnings this Week: How Will it Perform?
- Aptose Biosciences presents highlights from webcast on tuspetinib